Influence of adenosine receptor agonists on benzodiazepine withdrawal signs in mice.
The involvement of adenosine receptor agonists in benzodiazepine withdrawal signs was evaluated as the seizure susceptibility of mice. The concomitant administration of subthreshold dose of pentetrazole (55.0 or 60.0 mg/kg, s.c.) with flumazenil (10.0 mg/kg, i.p.) in mice chronically treated with temazepam or diazepam induced the appearance of withdrawal signs: clonic seizures, tonic convulsions and death episodes. The administration of the selective A1 (CPA-N6-cyclopentyladenosine), A2A (CGS 21680-2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine hydrochloride) and the non-selective A1/A2A (NECA-5'-N-ethylcarboxamidoadenosine) adenosine receptor agonists (i.p.) evoked the significant attenuation of benzodiazepine withdrawal signs, and these effects were more expressed in temazepam- than in diazepam-dependent mice. CPA has shown the most apparent and dose-dependent attenuating effect. The results confirm that adenosine A1 and A2A receptors are involved in benzodiazepine withdrawal signs, and adenosine A1 receptor plays a predominant role in this phenomenon.
Listos
Joanna
J
Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, Staszica 4, 20-081 Lublin, Poland. alistos@op.pl
Malec
Danuta
D
Fidecka
Sylwia
S
D000241:Adenosine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D019830:Adenosine-5'-(N-ethylcarboxamide) / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000927:Anticonvulsants / Q000008:administration & dosage / Q000494:pharmacology*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects*; D003975:Diazepam / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005442:Flumazenil; D008297:Male; D051379:Mice; D010433:Pentylenetetrazole; D010627:Phenethylamines / Q000008:administration & dosage / Q000494:pharmacology; D058913:Purinergic Agonists; D058906:Purinergic P1 Receptor Agonists; D058910:Purinergic P2 Receptor Agonists; D012640:Seizures / Q000139:chemically induced / Q000517:prevention & control*; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control*; D013693:Temazepam / Q000008:administration & dosage / Q000009:adverse effects
D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D010627:Phenethylamines; D058913:Purinergic Agonists; D058906:Purinergic P1 Receptor Agonists; D058910:Purinergic P2 Receptor Agonists; C061282:2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine; D001569:Benzodiazepines; D019830:Adenosine-5'-(N-ethylcarboxamide); D005442:Flumazenil; C048599:N(6)-cyclopentyladenosine; D013693:Temazepam; D000241:Adenosine; D003975:Diazepam; D010433:Pentylenetetrazole